PSNL Stock Overview
Develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Personalis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.69 |
| 52 Week High | US$7.20 |
| 52 Week Low | US$0.89 |
| Beta | 1.92 |
| 11 Month Change | 27.58% |
| 3 Month Change | 318.38% |
| 1 Year Change | 306.43% |
| 33 Year Change | -74.58% |
| 5 Year Change | -65.33% |
| Change since IPO | -80.03% |
Recent News & Updates
Investors Still Aren't Entirely Convinced By Personalis, Inc.'s (NASDAQ:PSNL) Revenues Despite 28% Price Jump
Sep 14
A Piece Of The Puzzle Missing From Personalis, Inc.'s (NASDAQ:PSNL) 131% Share Price Climb
Jul 25Recent updates
Investors Still Aren't Entirely Convinced By Personalis, Inc.'s (NASDAQ:PSNL) Revenues Despite 28% Price Jump
Sep 14A Piece Of The Puzzle Missing From Personalis, Inc.'s (NASDAQ:PSNL) 131% Share Price Climb
Jul 25Market Cool On Personalis, Inc.'s (NASDAQ:PSNL) Revenues Pushing Shares 25% Lower
Apr 19Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 31% Yet They're Still Not Telling The Full Story
Mar 02Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 37% Yet They're Still Not Telling The Full Story
Dec 18Will Personalis (NASDAQ:PSNL) Spend Its Cash Wisely?
Dec 04Personalis (NASDAQ:PSNL) Will Have To Spend Its Cash Wisely
Sep 04Investors Holding Back On Personalis, Inc. (NASDAQ:PSNL)
Apr 17The Prognosis For Personalis
Jun 16Health Check: How Prudently Does Personalis (NASDAQ:PSNL) Use Debt?
Jun 09Is Personalis (NASDAQ:PSNL) Using Debt In A Risky Way?
Feb 17Personalis: Getting Personal Again
Feb 02Health Check: How Prudently Does Personalis (NASDAQ:PSNL) Use Debt?
Nov 11Companies Like Personalis (NASDAQ:PSNL) Are In A Position To Invest In Growth
Oct 12Shareholder Returns
| PSNL | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 6.0% | 1.3% | 4.2% |
| 1Y | 306.4% | 7.4% | 24.4% |
Return vs Industry: PSNL exceeded the US Life Sciences industry which returned 7% over the past year.
Return vs Market: PSNL exceeded the US Market which returned 22% over the past year.
Price Volatility
| PSNL volatility | |
|---|---|
| PSNL Average Weekly Movement | 26.4% |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PSNL's share price has been volatile over the past 3 months.
Volatility Over Time: PSNL's weekly volatility has increased from 19% to 26% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 224 | Chris Hall | www.personalis.com |
Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample.
Personalis, Inc. Fundamentals Summary
| PSNL fundamental statistics | |
|---|---|
| Market cap | US$324.87m |
| Earnings (TTM) | -US$81.45m |
| Revenue (TTM) | US$80.03m |
4.0x
P/S Ratio-4.0x
P/E RatioIs PSNL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PSNL income statement (TTM) | |
|---|---|
| Revenue | US$80.03m |
| Cost of Revenue | US$57.81m |
| Gross Profit | US$22.22m |
| Other Expenses | US$103.67m |
| Earnings | -US$81.45m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.44 |
| Gross Margin | 27.76% |
| Net Profit Margin | -101.78% |
| Debt/Equity Ratio | 2.0% |
How did PSNL perform over the long term?
See historical performance and comparison